Trials / Recruiting
RecruitingNCT06297226
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 230 (estimated)
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Arlocabtagene Autoleucel | Specified dose on specified days |
Timeline
- Start date
- 2024-03-21
- Primary completion
- 2027-06-30
- Completion
- 2032-06-30
- First posted
- 2024-03-07
- Last updated
- 2026-02-10
Locations
52 sites across 4 countries: United States, Australia, Canada, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06297226. Inclusion in this directory is not an endorsement.